SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that Dr. Alexandre Abizaid, Director of Invasive Cardiology at the Institute Dante Pazzanese of Cardiology, in Sao Paulo, Brazil, will present an update on the Company's Fantom clinical trial program at the Paris Course on Revascularization ("EuroPCR"). EuroPCR is being held May 19th through 22nd in Paris, France. Dr. Abizaid is scheduled to present during the Cardiovascular Innovations Pipeline session on Thursday, May 21, 2015 at 2:50 p.m. CEST.
The presentation materials delivered at the conference will be available in the Investor Relations section of REVA's website at www.revamedical.com on the day of the presentation.
About REVA
REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called "scaffolds" because of their temporary nature. The Company's scaffolds are currently in clinical studies and have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company's initial intended commercial product, the FantomTM scaffold, has been designed to offer distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.